DOI: 10.36347/sjams.2019.v07i02.020

Pages: 530-534

Myasthenia gravis is an autoimmune disease with a great impact on quality of life. Thymectomy is a frequently used treatment for myasthenia gravis (MG) and is virtually always indicated in MG patients who have a thymoma. Throughout history, Thymectomy for nonthymomatous myasthenia gravis improved clinical outcomes, that supported by a randomised controlled trial. The surgical approach almost performed for the past decade has been a mini-invasive surgery (MIS). Methods: We retrospectively reviewed 48 patients with myasthenia gravis undergoing thymectomy between January 2008 and December 2015. The aim of this study was to determine the outcome of the long-time results after thymectomy for all the patients paying special attention to postoperative disease-related outcomes, quality of life, and differences regarding the operative approach. Results: 48 patients with myasthenia gravis were followed up after thymectomy for a median time of 4.58 years (range, 1–8 years). Our results indicated that the hospital stay was significantly shorter with minimally invasive procedures, overall, perioperative complications were found in 25 patients (52.08%).